Genetically engineered human induced pluripotent stem cells for the production of brain-targeting extracellular vesicles

• Published in: Stem cell research & therapy Vol. 15; no. 1; p. 345
• Main Authors: Tang, Fan, Dong, Tao, Zhou, Chengqian, Deng, Leon, Liu, Hans B, Wang, Wenshen, Liu, Guanshu, Ying, Mingyao, Li, Pan P
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.10.2024; BioMed Central
• Subjects: Animals; Brain - metabolism; Chromosomes; CRISPR-Cas Systems; Drug delivery systems; Drugs; Ethylenediaminetetraacetic acid; Extracellular Vesicles - metabolism; Genetic Engineering; Genetically modified organisms; Glycoproteins - genetics; Glycoproteins - metabolism; Health aspects; Humans; Induced Pluripotent Stem Cells - cytology; Induced Pluripotent Stem Cells - metabolism; Mice; Neurons; Peptide Fragments; Peptides; Scientific equipment and supplies industry; Stem cells; Vehicles; Viral Proteins; United States
• ISSN: 1757-6512; 1757-6512
• DOI: 10.1186/s13287-024-03955-2

Extracellular vesicles (EVs) are cell-secreted membrane vesicles that have become a promising, natural nanoparticle system for delivering either naturally carried or exogenously loaded therapeutic molecules. Among reported cell sources for EV manufacture, human induced pluripotent stem cells (hiPSCs) offer numerous advantages. However, hiPSC-EVs only have a moderate ability for brain delivery. Herein, we sought to develop a stable hiPSC line for producing EVs with substantially enhanced brain targeting by genetic engineering to overexpress rabies viral glycoprotein (RVG) peptide fused to the N terminus of lysosomal associated membrane protein 2B (RVG-Lamp2B) which has been shown capable of boosting the brain delivery of EVs via the nicotinic acetylcholine receptor. An RVG-Lamp2B-HA expression cassette was knocked into the AAVS1 safe harbor locus of a control hiPSC line using the CRISPR/Cas9-assisted homologous recombination. Western blot was used to detect the expression of RVG-Lamp2B-HA in RVG-edited hiPSCs as well as EVs derived from RVG-edited hiPSCs. Uptake of EVs by SH-SY5Y cells in the presence of various endocytic inhibitors was analyzed using flow cytometry. Biodistribution and brain delivery of intravenously injected control and RVG-modified EVs in wild-type mice were examined using ex vivo fluorescent imaging. Here we report that an RVG-Lamp2B-HA expression cassette was knocked into the AAVS1 safe harbor locus of a control hiPSC line using the CRISPR/Cas9-assisted homologous recombination. The RVG-edited iPSCs have normal karyotype, express pluripotency markers, and have differentiation potential. Expression of RVG-Lamp2B-HA was detected in total cell extracts as well as EVs derived from RVG-edited (vs. control) hiPSCs. The RVG-modified EVs enter neuronal cells via distinct endocytic pathways, compared with control EVs. The biodistribution study confirmed that EVs derived from RVG-edited hiPSCs possess higher brain delivery efficiency. Taken together, we have established stable, genetically engineered hiPSCs for producing EVs with RVG expression, offering the improved ability for brain-targeted drug delivery.